Xiaoli Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiaoli Cheng has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Chaonan Sun
Department of Radiation Oncology, Liaoning Cancer Hospital & Institute, Cancer Hospital of China Medical University, Shenyang, China
1 shared publication Cheng Cheng
Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang, China
1 shared publication- Long Zhou
Department of Orthopedics, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, 110004, China
1 shared publication - Yifan Yu
Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, 110004, China
1 shared publication - Yongnan Li
Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, 110004, China
1 shared publication Zheng Gong
Department of Radiology, Shengjing Hospital of China Medical University, Shenyang, China
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 2 May 2025
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 44 (1) , 1-32
Harnessing engineered extracellular vesicles for enhanced therapeutic efficacy: advancements in cancer immunotherapy
Extracellular vesicles (EVs), particularly engineered variants, have emerged as promising tools in cancer immunotherapy due to their inherent ability to modulate immune responses and deliver therapeutic agents with high specificity and minimal toxicity. These nanometer-sized vesicles, which include exosomes (Exos) and other subtypes, naturally participate in intercellular communication and are capable of carrying a diverse range of bioactive molecules, including proteins, lipids, RNAs, and metabolites. Recent advancements in the biogenesis of engineered EVs, such as strategies to modify their surface characteristics and cargo, have significantly expanded their potential as effective vehicles for targeted cancer therapies. Tailoring the contents of EVs, such as incorporating immunomodulatory molecules or gene-editing tools (GETs), has shown promising outcomes in enhancing anti-tumor immunity and overcoming the immunosuppressive tumor microenvironment (TME). Moreover, optimizing delivery mechanisms, through both passive and active targeting strategies, is crucial for improving the clinical efficacy of EV-based therapies. This review provides an overview of recent developments in the engineering of EVs for cancer immunotherapy, focusing on their biogenesis, methods of content customization, and innovations in cargo delivery. Additionally, the review addresses the challenges associated with the clinical translation of EV-based therapies, such as issues related to scalability, safety, and targeted delivery. By offering insights into the current state of the field and identifying key areas for future research, this review aims to advance the application of engineered EVs in cancer treatment.
- 2 May 2025
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 44 (1) , 1-32
Top Cited PapersOpen AccessHarnessing engineered extracellular vesicles for enhanced therapeutic efficacy: advancements in cancer immunotherapy
Extracellular vesicles (EVs), particularly engineered variants, have emerged as promising tools in cancer immunotherapy due to their inherent ability to modulate immune responses and deliver therapeutic agents with high specificity and minimal toxicity. These nanometer-sized vesicles, which include exosomes (Exos) and other subtypes, naturally participate in intercellular communication and are capable of carrying a diverse range of bioactive molecules, including proteins, lipids, RNAs, and metabolites. Recent advancements in the biogenesis of engineered EVs, such as strategies to modify their surface characteristics and cargo, have significantly expanded their potential as effective vehicles for targeted cancer therapies. Tailoring the contents of EVs, such as incorporating immunomodulatory molecules or gene-editing tools (GETs), has shown promising outcomes in enhancing anti-tumor immunity and overcoming the immunosuppressive tumor microenvironment (TME). Moreover, optimizing delivery mechanisms, through both passive and active targeting strategies, is crucial for improving the clinical efficacy of EV-based therapies. This review provides an overview of recent developments in the engineering of EVs for cancer immunotherapy, focusing on their biogenesis, methods of content customization, and innovations in cargo delivery. Additionally, the review addresses the challenges associated with the clinical translation of EV-based therapies, such as issues related to scalability, safety, and targeted delivery. By offering insights into the current state of the field and identifying key areas for future research, this review aims to advance the application of engineered EVs in cancer treatment.
- Top Cited Papers
- 10 September 2024
- Published by Elsevier in Cancer Letters
- Vol. 604, 217243
Hepatic stellate cells promote hepatocellular carcinoma development by regulating histone lactylation: Novel insights from single-cell RNA sequencing and spatial transcriptomics analyses
- 10 September 2024
- Published by Elsevier in Cancer Letters
- Vol. 604, 217243
Top Cited PapersHepatic stellate cells promote hepatocellular carcinoma development by regulating histone lactylation: Novel insights from single-cell RNA sequencing and spatial transcriptomics analyses